Bright Minds Biosciences Inc (DRUG)

Nov 9, 2026

Levi & Korsinsky is investigating Bright Minds Biosciences (NASDAQ: DRUG) following a sharp selloff in its shares. The selloff occurred after the FDA placed a partial clinical hold on the Company's planned Phase 2 BMB-101 pediatric epilepsy trial, citing toxicity findings in mice and insufficient data. The law firm is investigating potential securities law violations on behalf of investors who suffered losses.

Nov 8, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has received a consensus "Moderate Buy" rating from twelve research firms, with an average 12-month price target of $126.29, despite some recent analyst downgrades. The company reported a quarterly adjusted loss of $0.17 per share, significantly better than the consensus estimate of a $1.22 loss. Shares opened at $23, reflecting a 52-week range of $17.40 to $123.75, and institutional investors own 40.52% of the stock.

Nov 6, 2026

This article provides a price-driven insight into Bright Minds Biosciences Inc. (NASDAQ: DRUG) for a rule-based trading strategy. It highlights weak sentiment across all time horizons, supporting a short bias, and outlines three AI-generated trading strategies: Position Trading (Long), Momentum Breakout (Breakout), and Risk Hedging (Short), complete with profit targets and stop-loss levels. The analysis emphasizes elevated downside risk due to a lack of long-term support signals.

Nov 4, 2026

Robert W. Baird has lowered its price target for Bright Minds Biosciences (NASDAQ:DRUG) from $126 to $107, while maintaining an "outperform" rating, suggesting a significant upside. This adjustment comes amidst a mixed analyst sentiment, with the company facing recent downgrades and a partial clinical hold on its BMB-101 study by the FDA due to toxicity concerns in mice. Despite these challenges, Bright Minds Biosciences reported a smaller-than-expected quarterly loss of $0.17 per share, significantly beating analyst estimates.

Nov 2, 2026

Levi & Korsinsky is investigating Bright Minds Biosciences (NASDAQ: DRUG) on behalf of investors who suffered losses after the FDA placed its planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data as reasons for the hold. Shareholders are encouraged to contact Levi & Korsinsky for a free review of their potential legal rights.

Nov 2, 2026

The U.S. Food and Drug Administration has placed a partial clinical hold on Bright Minds Biosciences' investigational new drug application for BMB-101 in developmental and epileptic encephalopathies, citing juvenile toxicity concerns observed in mice. This regulatory pause impacts the planned Phase 2 trial in the U.S. The company plans to address the FDA's concerns and refines its protocol, while emphasizing that internal reviews suggest the mouse toxicity findings were incidental. Bright Minds Biosciences shares (NASDAQ: DRUG) traded 55% lower following the announcement.

Nov 2, 2026

Bright Minds Biosciences announced a partial clinical hold from the FDA on its planned U.S. seizure trial for BMB-101. The FDA cited concerns regarding mouse toxicity and insufficient pediatric data to support enrolling children in the Phase 2 protocol (BMB-101-105). The company is awaiting the full clinical hold letter to understand the detailed requirements for resolution, although it believes the hold only impacts the U.S. study.

Nov 2, 2026

Bright Minds Biosciences has received a partial clinical hold from the FDA for its BMB-101 Phase 2 trial in the US, aimed at treating developmental and epileptic encephalopathies (DEEs). The hold is due to toxicity findings in mice and insufficient data on pharmacokinetics and juvenile toxicity, specifically concerning the proposed enrollment of pediatric patients. The company plans to address these concerns with the FDA and modify the study design as needed.

Oct 30, 2026

Bright Minds Biosciences Inc. (CN:DRUG :CNX) saw its share price advance by 2.08%, signaling positive investor sentiment. The company, focused on clinical-stage neuroscience and psychedelic-inspired therapeutics, presents long-term operating and strategic opportunities. Sustained re-rating will depend on fundamental progress, execution, cash generation, and balance-sheet flexibility.

Oct 30, 2026

Bright Minds Biosciences Inc. (CN:DRUG :CNX) saw its share price advance by 2.08% during the October 29, 2026 trading session, though no specific catalyst for the move has been identified. The clinical-stage biotechnology company, which focuses on novel therapeutics for neurological and psychiatric disorders, operates in a sector where investor assessment is influenced by market demand, competitive positioning, and operating execution. The article suggests that sustaining this positive trend will depend on the company's financial resilience, execution of strategic priorities, and overall market conditions.